Pfizer (PFE) Stock Forecast & Price Target

Pfizer is viewed favorably because its products, pipeline, and execution continue to exceed expectations, supporting a stronger long-term fundamental profile. The company’s roughly $60 billion in annual sales are anchored by prescription drugs and vaccines, with top sellers such as Prevnar 13, Vyndamax, and Eliquis providing diversified revenue and meaningful scale. Its global reach, including 40% of sales from international markets and a major contribution from emerging markets, along with an expected return to growth by the end of the decade as the R&D pipeline matures and commercial execution remains strong, reinforces the positive outlook.

Pfizer is facing a weaker fundamental backdrop as 2026 guidance already embeds an expected year-over-year revenue hit of about $1.1 billion from loss of exclusivity, while key products such as Prevnar, Comirnaty, and Paxlovid are seeing softer estimates and commercial execution risk. The company’s outlook is further pressured by declining vaccination rates, lower birth rates, U.S. vaccine policy, FX, and the timing of its international year-end on August 31, which delays any benefit from the updated COVID vaccine until September. Competitive intensity remains high across its portfolio, with products and pipeline candidates vulnerable to lower rebates, generic and biosimilar pressure, pricing reform, tariff policy, and potential clinical or regulatory setbacks.